Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) EPS (Weighted Average and Diluted) (2016 - 2025)

Anaptysbio (ANAB) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with $1.7 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 369.84% year-over-year to $1.7, compared with a TTM value of -$0.46 through Dec 2025, up 91.02%, and an annual FY2025 reading of -$0.46, up 91.02% over the prior year.
  • EPS (Weighted Average and Diluted) was $1.7 for Q4 2025 at Anaptysbio, up from $0.46 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.7 in Q4 2025 and bottomed at -$1.71 in Q2 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.92, with a median of -$1.18 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 5650.0% in 2022, then surged 369.84% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$1.19 in 2021, then rose by 21.85% to -$0.93 in 2022, then plummeted by 70.97% to -$1.59 in 2023, then soared by 60.38% to -$0.63 in 2024, then soared by 369.84% to $1.7 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ANAB at $1.7 in Q4 2025, $0.46 in Q3 2025, and -$1.34 in Q2 2025.